Earnings summaries and quarterly performance for Cytek Biosciences.
Executive leadership at Cytek Biosciences.
Board of directors at Cytek Biosciences.
Research analysts who have asked questions during Cytek Biosciences earnings calls.
David Westenberg
Piper Sandler
8 questions for CTKB
Also covers: ADPT, AKYA, DGX +12 more
Chad Wiatrowski
TD Cowen
7 questions for CTKB
Also covers: BLFS, CDXS, MASS +4 more
Harrison Parsons
Stephens
6 questions for CTKB
Also covers: CUTR, HOLX, PACB
Noah Lewis
Raymond James
6 questions for CTKB
Also covers: OSUR
Andrew Cooper
Raymond James
2 questions for CTKB
Also covers: AZTA, CDNA, EXAS +12 more
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for CTKB
Also covers: A, ADPT, AVTR +21 more
Tejas Savant
Morgan Stanley
2 questions for CTKB
Also covers: ADPT, AKYA, AVTR +19 more
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
1 question for CTKB
Also covers: ABCL, ABSI, ARWR +19 more
Mason Carrico
Stephens Inc.
1 question for CTKB
Also covers: AKYA, CDNA, CSTL +13 more
Matt Sykes
Goldman Sachs Group, Inc.
1 question for CTKB
Also covers: CRL, MRVI, NTRA +4 more
Yih-Ming Tu
Morgan Stanley
1 question for CTKB
Also covers: CYRX
Recent press releases and 8-K filings for CTKB.
Cytek Biosciences Discusses Q3 Performance, Market Growth, and New Product Adoption
CTKB
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Cytek Biosciences reported positive revenue growth in Q3 and reiterated guidance, with management suggesting a potential return to normal growth and a bottoming in the overall flow cytometry market.
- 85% of Cytek's business, encompassing service, reagents, and instruments (excluding Europe), is experiencing double-digit growth, with strong performance anticipated in Asia-Pac and stabilization in the US.
- The company launched the Aurora Evo in June, an instrument designed for pharmaceutical companies with advanced features like automated operations and higher throughput, which is expected to comprise a large majority of future instrument sales due to its price premium and capabilities.
- Reagent revenue is a key growth driver, increasing at a double-digit rate (close to 20% year-over-year), significantly outpacing the broader market's 1% growth in Q3, and represents a potential $150 million to $200 million opportunity from the installed base.
- Challenges in the European market for instrument sales in 2025 were attributed to a slowdown in biopharma spending and reduced government funding, though this segment constitutes only 15% of the total business, and the rate of decline is expected to slow in Q4 2025.
2 days ago
Cytek Discusses Q3 Performance, Aurora Evo Launch, and Reagent Growth
CTKB
Revenue Acceleration/Inflection
Product Launch
Demand Weakening
- Cytek reported positive revenue growth in Q3, with 85% of its business segments (service, reagents, and instruments excluding Europe) experiencing double-digit growth.
- The recently launched Aurora Evo instrument, tailored for pharmaceutical companies with enhanced features, is anticipated to represent a large majority of Cytek's instrument sales by 2026 and carries a price premium.
- Reagent sales demonstrated robust performance, growing at a double-digit rate, close to 20% year over year, significantly outperforming the broader market's 1% growth in Q3.
- Despite challenges in EMEA instrument sales in 2025, the company's business excluding EMEA instruments grew 11% in Q3, and EMEA reagent growth is the fastest across all territories.
2 days ago
Cytek Biosciences Discusses Q3 Performance and Market Outlook
CTKB
Revenue Acceleration/Inflection
Product Launch
Demand Weakening
- Cytek Biosciences reported positive revenue growth in Q3, with CFO Bill McCombe indicating a potential return to normal growth and a bottoming in the overall flow cytometry market.
- 85% of the business is experiencing double-digit growth, encompassing service, reagents, and instrument sales in all regions except Europe; Asia-Pac is projected for continued strong growth, and the US market is stabilizing.
- The Aurora Evo instrument, launched in June, is tailored for pharmaceutical companies, featuring capabilities like nanoparticle detection and automated operations, and is anticipated to constitute a large majority of instrument sales by 2026 at a price premium.
- Reagent growth is robust, nearing 20% year-over-year, significantly outperforming the overall market's 1% growth in Q3, with substantial future opportunities from the existing installed base.
- Instrument sales in Europe (EMEA) faced challenges in 2025 due to high prior growth in biopharma and reduced government funding, but the rate of decline is expected to slow in Q4, with easier comparisons anticipated in 2026.
2 days ago
Cytek Biosciences Reports Q3 2025 Financial Results with 2% Revenue Growth
CTKB
Earnings
Guidance Update
Demand Weakening
- Total revenue for Q3 2025 reached $52.3 million, marking a 2% year-over-year increase, primarily fueled by strong double-digit growth in the Asia-Pacific region and continued momentum in service and reagents.
- Regional performance showed APAC revenue up 25% and U.S. revenue up 12%, while EMEA experienced a 28% decline due to reduced instrument sales to academic and government customers.
- GAAP gross profit margin decreased to 53% from 56% in Q3 2024, and the company reported a net loss of $5.5 million for the quarter.
- Adjusted EBITDA was $2.5 million, down from $7.6 million in the prior year quarter, and free cash flow was -$0.3 million, with $261.7 million in cash and marketable securities.
- Cytek reaffirmed its full-year 2025 revenue outlook of $196 million-$205 million, anticipating continued strong growth in APAC instruments, stabilization in U.S. instruments, and solid growth in recurring revenue businesses.
Nov 5, 2025, 9:30 PM
Cytek Biosciences Reports Third Quarter 2025 Financial Results
CTKB
Earnings
Guidance Update
Demand Weakening
- Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024, with growth in the US, APAC, and rest-of-world partially offset by continued softness in EMEA.
- The company reported a net loss of $5.5 million in the third quarter of 2025, compared to a net income of $0.9 million in the third quarter of 2024.
- GAAP gross profit margin was 53% in the third quarter of 2025, down from 56% in the prior year period. Operating expenses increased 10% to $36.7 million, driven by a 47% increase in general and administrative expenses due to litigation-related expenses and a non-recurring charge.
- Adjusted EBITDA for the third quarter of 2025 was $2.5 million, compared to $7.6 million in the third quarter of 2024.
- Cytek Biosciences reaffirmed its full year 2025 revenue guidance to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024.
Nov 5, 2025, 9:15 PM
Quarterly earnings call transcripts for Cytek Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more